Note some upcoming possible catalysts
$VYNE Therapeutics (VYNE.US)$ Phase 1a SAD/MAD trial of VYN202 progressing, with data from the SAD and MAD portions expected in Q3 and Q4 2024, respectivelyUpcoming Conference Participation•H.C. Wainwright 26th Annual Global Investment Conference, September 9-11, 2024, New York, NY•Stifel Immunology and Inflammation Virtual Summit, September 17-18, 2024
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more